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Hemoglobin response to
ferric citrate in patients with
nondialysis-dependent chronic
kidney disease and iron
deficiency anemia
To the Editor:
Anemia is a common complication in patients with chronic kidney dis-
ease (CKD) and often occurs due to iron deficiency. Causes of iron
deficiency in CKD include upregulation of hepcidin (a peptide hormone
that reduces iron transport across enterocytes) leading to decreased
dietary iron absorption, impaired iron release from body stores associ-
ated with heightened inflammation, and gastrointestinal blood loss. All
result in insufficient bone marrow iron availability and inefficient eryth-
ropoiesis, leading to iron deficiency anemia.1
Recent clinical practice guidelines from Kidney Disease: Improving
Global Outcomes recommend using oral or intravenous iron before
erythropoietin-stimulating agents for the treatment of iron deficiency
anemia in patients with nondialysis-dependent (NDD)-CKD.1 Oral iron
preparations are typically ineffective and/or poorly tolerated due to
gastrointestinal side effects.1 Intravenous iron is used infrequently in
nephrology offices as it requires intravenous infusion in a monitored
setting with facilities for resuscitation because of risks of serious
adverse drug events, including hypersensitivity reactions.1
In a randomized placebo-controlled trial of ferric citrate in 234
patients with NDD-CKD and iron deficiency anemia,2 ferric citrate-
treated patients were significantly more likely to achieve a 1.0 g/dL
increase in hemoglobin (52.1% vs. 19.1% with placebo; P< .001) during
the 16-week randomized phase; the least-squares mean (LSM) relative
change in hemoglobin was 0.84 g/dL (95% confidence interval [CI],
0.58-1.10).2
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The current analysis examined associations of baseline demo-
graphic, clinical, and laboratory variables with change in hemoglobin. It
was hypothesized that patients with biochemical evidence of more
severe iron deficiency would experience a more pronounced hemoglo-
bin response.
Adult patients with iron deficiency anemia (hemoglobin 9.0–11.5 g/dL;
transferrin saturation [TSAT]25%; ferritin200 ng/mL) and NDD-
CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) were
included in the trial. Full clinical trial details are described elsewhere.2
Here, multivariable linear regression analysis was used to identify vari-
ables associated with change in hemoglobin from baseline to week
16. Candidate variables were included in models based on forward
selection and backward elimination using the Akaike information cri-
terion (AIC). Treatment (ferric citrate vs. placebo) and baseline hemo-
globin were fixed in all models. Potential interactions between
treatment and each baseline variable were tested sequentially using
stepwise AIC. For baseline variables with retained treatment interac-
tion terms, mixed-effect models for repeated measures were fitted to
confirm treatment interactions using all available longitudinal data
and to assess the magnitude of treatment differences by baseline
covariate levels (estimated at 25th and 75th percentiles). Two-tailed
P-values <.05 were considered statistically significant. See Supporting
Information Material for further detail.
Overall, 234 patients were randomized to receive ferric citrate
(n5117) or placebo (n5117). This post hoc analysis employed the
intention-to-treat population (ferric citrate, n5117; placebo, n5115),
and baseline characteristics were similar across groups (Supporting
Information Table S1).2
Among ferric citrate-treated patients, observed mean hemoglobin
(standard deviation) increased from 10.4 g/dL (0.7) at baseline to
11.4 g/dL (1.1) at week 16.
The following variables were significantly associated with greater
hemoglobin increases from baseline at 16 weeks: ferric citrate treat-
ment (P< .0001), lower baseline hemoglobin (P5 .0160), higher serum
albumin (P5 .0007), lower intact fibroblast growth factor 23 (FGF23;
P5 .0024), and lower TSAT (P5 .0189) (Supporting Information Table
S2; Sensitivity Analyses). Treatment interactions were retained for
TSAT and ferritin only.
The treatment effect of ferric citrate versus placebo on hemoglo-
bin was greater among patients with lower baseline TSAT than those
with higher baseline TSAT. The estimated LSM difference at 16 weeks
was 1.16 g/dL (95% CI, 0.84-1.48; P< .0001) at TSAT 15% and 0.78 g/dL
(95% CI, 0.48-1.08; P< .0001) at TSAT 24% (treatment 3 baseline
TSAT 3 week 16 interaction P5 .0426). Ferric citrate-treated
patients with lower versus higher baseline TSAT showed a greater
rate of hemoglobin rise (Figure 1A).
Similarly, the treatment effect of ferric citrate versus placebo
was greater among patients with lower baseline ferritin (estimated
LSM difference at ferritin 35 ng/mL, 1.12 g/dL; 95% CI, 0.78-1.45;
P< .0001) than patients with higher baseline ferritin (estimated
LSM difference at ferritin 126 ng/mL, 0.79 g/dL; 95% CI, 0.46-1.12;
P< .0001; treatment 3 baseline ferritin 3 week 16 interaction,
P5 .0974). Ferric citrate-treated patients with lower versus higher
baseline ferritin showed a greater rate of hemoglobin rise (Figure 1B).
These post hoc results indicate the association of baseline iron store
markers, namely TSAT and ferritin, with hemoglobin response to ferric
citrate treatment. While patients with lower baseline TSAT/ferritin experi-
enced a greater 16-week hemoglobin increase than those with higher
baseline TSAT/ferritin, hemoglobin increases versus placebo were also
significant among those with higher baseline TSAT/ferritin values, indicat-
ing that ferric citrate treatment is efficacious over a wide range of patients
with NDD-CKD. These data support current guidelines recommending a
trial of oral iron in patients with iron deficiency anemia and CKD and
FIGURE 1 Mean trajectories of change in hemoglobin (Hgb) over 16
weeks by treatment (ferric citrate vs. PBO) estimated at (A) baseline
(BL) TSAT level (15% vs. 24%) and (B) BL ferritin level (35 vs. 126 ng/
mL). For panel A, data are adjusted LSM (SE) change from BL derived
from an MMRM analysis with terms for treatment (ferric citrate vs.
PBO), BL albumin, BL log iFGF23, BL TSAT, week, treatment3 week
interaction, treatment3 TSAT interaction, and treatment3 week3
TSAT interaction as fixed effects, and BL Hgb as a covariate. For panel
B, data are adjusted LSM (SE) change from BL derived from an MMRM
analysis with terms for treatment (ferric citrate vs. PBO), BL albumin, BL
log iFGF23, BL TSAT, BL ferritin, week, treatment3 week interaction,
treatment3 ferritin interaction, and treatment3 week3 ferritin inter-
action as fixed effects, and BL Hgb as a covariate. Given the skewed
distribution of iFGF23, this variable was log-transformed before analy-
sis. **P< .01; ***P5 .001. CI, confidence interval; FC, ferric citrate; FER,
ferritin; iFGF23, intact fibroblast growth factor 23; LSM, least-squares
mean; MMRM, mixed model for repeated measures; PBO, placebo; SE,
standard error; TSAT, transferrin saturation
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suggest the need to identify more reliable clinical markers of bone marrow
iron availability.1
An important novel finding is the significant association of lower
baseline intact FGF23 and higher baseline serum albumin with greater
hemoglobin increase. No association was observed with c-terminal
FGF23, presumably because cleavage of active/intact FGF23 is not
impaired in the setting of iron deficiency.5 In the setting of inflammation,
serum ferritin and intact FGF23 are increased, while serum albumin is
decreased.5,6 However, serum ferritin also decreases with iron deficiency.
Thus, in patients with CKD, the hemoglobin response to iron is probably
dependent on various degrees of inflammation and iron deficiency ane-
mia. This impedes the predictive utility of ferritin and even TSAT.
This study is limited by the post hoc and exploratory nature of
these analyses. Results should be verified by randomized, prospective
trials that focus on optimizing anemia management while achieving a
steady state for iron parameters.
In summary, while hemoglobin increased in nearly all patients with iron
deficiency anemia and NDD-CKD over 16 weeks of ferric citrate treatment,
patients with biochemical markers of more severe iron deficiency experi-
enced more pronounced increases in hemoglobin concentration.
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